Gustav Cederquist, an MD-PhD student in Dr. Lorenz Studer’s lab, has won first runner-up/honorable mention for the 2016 Regeneron Prize for Creative Innovation.
The Regeneron Creative Innovation Prize honors students and postdoctoral fellows who have had particularly productive early scientific careers. Each contestant is asked to write a "dream project" proposal. The proposal aims to distinguish scientists who are productive because of their labs versus those who are independently creative.
Gustav’s dream project titled “A human pluripotent stem cell-based platform for directed evolution of viral tropism to generate celltype specific vectors for gene therapy” earned him one of the five student finalists. The finalists visited Regeneron and presented their work to Regeneron scientists. Gustav is the first student from Weill Cornell to receive a Regeneron award in the prize’s 4-year history.
Congratulations to Gustav!
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron commercializes medicines for eye diseases and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis. For additional information about the company, please visit www.regeneron.com.